HealthcareHealthcare Equipment & SuppliesMedical Equipment & Supplies

Hemant Surgical Industries Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 23 filings·Updated 10 Jul 2026
Showing 10 of 23 filings.
10 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5): not applicable; all shares are in demat form, with no requests

Dematerialisation status

  • Not applicable; entire holding in demat form, no rematerialisation requests.
  • No dematerialisation/rematerialisation requests were received during the period.
Filed 15:53View Source
9 Jun 20261 filing
Company UpdatePress Release / Media Release

Hemant Surgical Industries Ltd - 543916 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Acquisition

  • Hemant Surgical acquired 66.66% of Lifesenz Cancer Research Labs for Rs. 19.98 crore.
  • Lifesenz became a subsidiary effective June 1, 2026.

Business focus

  • Lifesenz operates in precision oncology and personalized cancer treatment solutions.
  • It uses ex-vivo chemo-sensitivity analysis with patient-derived 3D cancer cell models.

Strategic impact

  • The acquisition expands Hemant Surgical beyond traditional healthcare distribution into advanced diagnostics.
  • Management expects stronger hospital and clinician relationships and future precision medicine expansion.

Financial outlook

  • Management said Lifesenz is in a growth phase and may take time to break even.
  • The deal was completed on an arm's length basis.

Operational plans

  • Hemant Surgical plans to scale operations, expand patient adoption, and increase commercialization opportunities.
Filed 13:27View Source
20 May 20262 filings
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Singularity Equity Fund I

Filed 10:09View Source
Insider Trading / SASTDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Singularity Large Value Fund III

Filed 10:07View Source
7 Apr 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026.

Filed 12:13View Source
27 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

Intimation of Closure of Trading Window

Filed 12:36View Source
12 Jan 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018.

Filed 12:47View Source
12 Nov 20252 filings
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation

Statement of Deviation or Variation for half year ended on September 30, 2025

Filed 18:05View Source
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation

Statement of Deviation or Variation for the half year ended on September 30, 2025.

Filed 18:01View Source
13 Oct 20251 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2025.

Filed 16:21View Source
Showing 10 of 23 filings